An orthotopic skull base model of malignant meningioma

被引:27
作者
Baia, Gilson S. [1 ]
Dinca, Eduard B. [1 ]
Ozawa, Tomoko [1 ]
Kimura, Edna T. [2 ]
McDermott, Michael W. [1 ]
James, C. David [1 ]
VandenBerg, Scott R. [1 ]
Lal, Anita [1 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94143 USA
[2] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, Sao Paulo, Brazil
关键词
bioluminescent imaging; IOMM-Lee; meningioma; orthotopic; skull base; xenografts;
D O I
10.1111/j.1750-3639.2007.00109.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Meningioma tumor growth involves the subarachnoid space that contains the cerebrospinal fluid. Modeling tumor growth in this microenvironment has been associated with widespread leptomeningeal dissemination, which is uncharacteristic of human meningiomas. Consequently, survival times and tumor properties are varied, limiting their utility in testing experimental therapies. We report the development and characterization of a reproducible orthotopic skull-base meningioma model in athymic mice using the IOMM-Lee cell line. Localized tumor growth was obtained by using optimal cell densities and matrigel as the implantation medium. Survival times were within a narrow range of 17-21 days. The xenografts grew locally compressing surrounding brain tissue. These tumors had histopathologic characteristics of anaplastic meningiomas including high cellularity, nuclear pleomorphism, cellular pattern loss, necrosis and conspicuous mitosis. Similar to human meningiomas, considerable invasion of the dura and skull and some invasion of adjacent brain along perivascular tracts were observed. The pattern of hypoxia was also similar to human malignant meningiomas. We use bioluminescent imaging to non-invasively monitor the growth of the xenografts and determine the survival benefit from temozolomide treatment. Thus, we describe a malignant meningioma model system that will be useful for investigating the biology of meningiomas and for preclinical assessment of therapeutic agents.
引用
收藏
页码:172 / 179
页数:8
相关论文
共 28 条
[1]
A genetic strategy to overcome the senescence of primary meningioma cell cultures [J].
Baia, Gilson S. ;
Slocum, Alison L. ;
Hyer, Jeanette D. ;
Misra, Anjan ;
Sehati, Nouzhan ;
VandenBerg, Scott R. ;
Feuerstein, Burt G. ;
Deen, Dennis F. ;
McDermott, Michael W. ;
Lal, Anita .
JOURNAL OF NEURO-ONCOLOGY, 2006, 78 (02) :113-121
[2]
DNA methylation of multiple promoter-associated CpG islands in meningiomas:: relationship with the allelic status at 1p and 22q [J].
Bello, MJ ;
Amiñoso, C ;
Lopez-Marin, I ;
Arjona, D ;
Gonzalez-Gomez, P ;
Alonso, M ;
Lomas, J ;
Campos, J ;
Kusak, M ;
Vaquero, J ;
Isla, A ;
Gutierrez, M ;
Sarasa, JL ;
Rey, JA .
ACTA NEUROPATHOLOGICA, 2004, 108 (05) :413-421
[3]
Burger P., 2002, Surgical pathology of the nervous system and its coverings, V4th edn
[4]
A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue [J].
Cankovic, Milena ;
Mikkelsen, Tom ;
Rosenblum, Mark L. ;
Zarbo, Richard J. .
LABORATORY INVESTIGATION, 2007, 87 (04) :392-397
[5]
Establishment of an in vivo meningioma model with human telomerase reverse transcriptase [J].
Cargioli, Theresa G. ;
Ugur, Hasan C. ;
Ramakrishna, Naren ;
Chan, Jennifer ;
Black, Peter M. ;
Carroll, Rona S. .
NEUROSURGERY, 2007, 60 (04) :750-759
[6]
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy [J].
Dinca, Eduard B. ;
Sarkaria, Jann N. ;
Schroeder, Mark A. ;
Carlson, Brett L. ;
Voicu, Ramona ;
Gupta, Nalin ;
Berger, Mitchel S. ;
James, C. David .
JOURNAL OF NEUROSURGERY, 2007, 107 (03) :610-616
[7]
Esteller M, 1999, CANCER RES, V59, P793
[8]
Friedman HS, 2000, CLIN CANCER RES, V6, P2585
[9]
Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter [J].
Hasegawa, K ;
Pham, L ;
O'Connor, MK ;
Federspiel, MJ ;
Russell, SJ ;
Peng, KW .
CLINICAL CANCER RESEARCH, 2006, 12 (06) :1868-1875
[10]
MGMT gene silencing and benefit from temozolomide in glioblastoma [J].
Hegi, ME ;
Diserens, A ;
Gorlia, T ;
Hamou, M ;
de Tribolet, N ;
Weller, M ;
Kros, JM ;
Hainfellner, JA ;
Mason, W ;
Mariani, L ;
Bromberg, JEC ;
Hau, P ;
Mirimanoff, RO ;
Cairncross, JG ;
Janzer, RC ;
Stupp, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003